ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY)
Historical Holders from Q2 2018 to Q4 2025
-
Type / Class
-
Equity / Common Stock, no par value
-
Symbol
-
ONCY on Nasdaq
-
Shares outstanding
-
109,272,143
-
Price per share
-
$0.8740
-
All holders as of 30 Sep 2025
-
Q3 2025
-
Total 13F shares as of 30 Sep 2025
-
2,820,198
-
Holdings value
-
$3,771,684
-
% of all portfolios
-
0%
-
Share change
-
+1,321,437
-
Value change
-
+$1,889,818
-
Average buys %
-
+0%
-
Average sells %
-
-0%
-
Number of holders
-
56
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Significant Owners of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) based on Schedule 13D/G filings
| Filer |
Ownership |
Change % |
Holdings Value |
Net Change |
Nb Shares |
Change % |
Reporting Name |
Report Period |
|
Anson Funds Management LP
|
7%
|
-26%
|
$10,708,670
|
-$751,370
|
7,649,050
|
-6.6%
|
Anson Funds Management LP
|
30 Sep 2025
|
As of 30 Sep 2025, ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) has 56 institutional shareholders filing 13F forms.
They hold 2,820,198 shares
of 109,272,143 outstanding shares (2.6%)
.
Institutional Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) across Reporting Periods
| Period |
Reported Shares, Excl. Options |
Value, Excl. Options |
Value Change |
Puts Notional Value |
Calls Notional Value |
Price |
Investors |
|
2025 Q4
|
25,000 |
$21,850 |
|
|
|
$0.8740 |
1 |
|
2025 Q3
|
2,820,198 |
$3,771,684 |
+$1,889,818 |
|
|
$1.40 |
56 |
|
2025 Q2
|
1,495,731 |
$1,150,336 |
+$116,133 |
|
|
$0.7730 |
54 |
|
2025 Q1
|
1,364,360 |
$748,757 |
-$5,861 |
|
|
$0.5500 |
50 |
|
2024 Q4
|
1,314,892 |
$1,206,107 |
+$64,784 |
|
|
$0.9138 |
46 |
|
2024 Q3
|
999,534 |
$872,336 |
-$113,469 |
|
|
$0.8710 |
40 |
|
2024 Q2
|
1,309,286 |
$1,297,302 |
-$118,709 |
|
|
$0.9900 |
41 |
|
2024 Q1
|
1,409,004 |
$1,495,371 |
-$5,110,399 |
|
|
$1.06 |
35 |
|
2023 Q4
|
5,144,044 |
$6,944,143 |
-$1,456,985 |
|
|
$1.35 |
42 |
|
2023 Q3
|
6,216,229 |
$13,562,379 |
+$11,870,396 |
|
|
$2.18 |
32 |
|
2023 Q2
|
800,773 |
$2,085,599 |
-$679,945 |
|
|
$2.60 |
28 |
|
2023 Q1
|
1,103,514 |
$1,325,529 |
+$296,418 |
|
|
$1.20 |
30 |
|
2022 Q4
|
902,111 |
$1,482,300 |
+$321,702 |
|
|
$1.63 |
33 |
|
2022 Q3
|
714,327 |
$883,809 |
-$184,426 |
|
|
$1.23 |
28 |
|
2022 Q2
|
909,878 |
$911,763 |
+$188,561 |
|
|
$1.00 |
33 |
|
2022 Q1
|
697,567 |
$1,099,375 |
-$760,113 |
|
|
$1.58 |
29 |
|
2021 Q4
|
1,187,087 |
$1,652,710 |
+$287,570 |
|
|
$1.40 |
34 |
|
2021 Q3
|
903,524 |
$1,890,946 |
-$125,314 |
|
|
$2.09 |
32 |
|
2021 Q2
|
887,682 |
$2,434,336 |
-$773,341 |
|
|
$2.77 |
35 |
|
2021 Q1
|
1,038,987 |
$3,786,537 |
+$314,929 |
|
|
$3.81 |
36 |
|
2020 Q4
|
1,085,633 |
$2,586,529 |
+$776,286 |
|
|
$2.38 |
30 |
|
2020 Q3
|
776,299 |
$1,313,572 |
-$60,476 |
|
|
$1.69 |
27 |
|
2020 Q2
|
828,293 |
$1,562,243 |
+$487,963 |
|
|
$1.88 |
30 |
|
2020 Q1
|
590,438 |
$816,220 |
+$77,206 |
|
|
$1.39 |
28 |
|
2019 Q4
|
384,390 |
$1,816,270 |
+$231,441 |
|
|
$4.75 |
23 |
|
2019 Q3
|
391,100 |
$223,581 |
-$568,195 |
|
|
$0.5828 |
12 |
|
2019 Q2
|
573,234 |
$975,780 |
+$645,305 |
|
|
$1.70 |
13 |
|
2019 Q1
|
193,664 |
$358,834 |
+$66,521 |
|
|
$1.87 |
17 |
|
2018 Q4
|
156,055 |
$282,469 |
-$180,670 |
|
|
$1.78 |
15 |
|
2018 Q3
|
184,782 |
$699,979 |
-$1,552,787 |
|
|
$3.83 |
16 |
|
2018 Q2
|
586,197 |
$3,220,392 |
+$3,220,392 |
|
|
$5.43 |
18 |